FDA Should Issue Pediatric Antidepressant Trial Summaries, Rep. Waxman Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The congressman's letter requests the immediate release of data for drugs that gained six months of additional exclusivity under the Best Pharmaceuticals for Children Act. While seven companies have gained exclusivity extensions for antidepressants, data on only two are available, he says.
You may also be interested in...
Antidepressant Manufacturers’ Trial Information Requested By Senate Cmte.
Finance Chairman Grassley asks eight manufacturers for list of all pediatric antidepressant trials, including completion, publication and FDA submission information. Grassley expresses concern that the firms may not have provided FDA with all the information “at their disposal.”
Antidepressant Manufacturers’ Trial Information Requested By Senate Cmte.
Finance Chairman Grassley asks eight manufacturers for list of all pediatric antidepressant trials, including completion, publication and FDA submission information. Grassley expresses concern that the firms may not have provided FDA with all the information “at their disposal.”
Clinicaltrials.gov: Rep. Waxman Wants PhRMA To Describe Steps To Improve Compliance
Waxman takes issue with PhRMA’s failure to appear at a recent House hearing to discuss FDA’s clinical trial registry. He asks the association to submit documents it has sent to member companies regarding compliance with the submission requirement.